{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T17:44:51Z","timestamp":1755798291480,"version":"3.44.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004396","name":"the Thailand Research Fund","doi-asserted-by":"crossref","award":["RSA 5780040"],"award-info":[{"award-number":["RSA 5780040"]}],"id":[{"id":"10.13039\/501100004396","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Health System Research Institute"},{"name":"the Research Chair grant from the National Research Council of Thailand","award":["N42A670594"],"award-info":[{"award-number":["N42A670594"]}]},{"name":"the Chiang Mai University Center of Excellence Award"},{"name":"a Distinguished Research Professor Grant from the National Research Council of Thailand and Chiang Mai University","award":["N42A660301"],"award-info":[{"award-number":["N42A660301"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-15104-7","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T14:47:19Z","timestamp":1755182839000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["FGF21 is a novel biomarker to predict fragility fractures in patients with type 2 diabetes mellitus"],"prefix":"10.1038","volume":"15","author":[{"given":"Mattabhorn","family":"Phimphilai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arintaya","family":"Phrommintikul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanwarang","family":"Wongcharoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natavuth","family":"Hengjeerajarus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krittadhee","family":"Karndumri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nipon","family":"Chattipakorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siriporn C.","family":"Chattipakorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"15104_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00198-011-1595-0","volume":"23","author":"A Shu","year":"2012","unstructured":"Shu, A. et al. Bone structure and turnover in type 2 diabetes mellitus. Osteoporos. Int. 23, 635\u2013641. https:\/\/doi.org\/10.1007\/s00198-011-1595-0 (2012).","journal-title":"Osteoporos. Int."},{"key":"15104_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00592-011-0347-0","volume":"50","author":"R Reyes-Garc\u00eda","year":"2013","unstructured":"Reyes-Garc\u00eda, R. et al. Serum levels of bone resorption markers are decreased in patients with type 2 diabetes. Acta Diabetol. 50, 47\u201352. https:\/\/doi.org\/10.1007\/s00592-011-0347-0 (2013).","journal-title":"Acta Diabetol."},{"key":"15104_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00223-015-0100-8","volume":"98","author":"J Paccou","year":"2016","unstructured":"Paccou, J. et al. Bone microarchitecture in men and women with diabetes: the importance of cortical porosity. Calcif Tissue Int. 98, 465\u2013473. https:\/\/doi.org\/10.1007\/s00223-015-0100-8 (2016).","journal-title":"Calcif Tissue Int."},{"key":"15104_CR4","doi-asserted-by":"publisher","unstructured":"Mart\u00ednez-Montoro, J. I., Garc\u00eda-Fontana, B., Garc\u00eda-Fontana, C. & Mu\u00f1oz-Torres, M. Evaluation of quality and bone microstructure alterations in patients with type 2 diabetes: A narrative review. J. Clin. Med. 11 https:\/\/doi.org\/10.3390\/jcm11082206 (2022).","DOI":"10.3390\/jcm11082206"},{"key":"15104_CR5","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1210\/jc.2006-0614","volume":"91","author":"DE Bonds","year":"2006","unstructured":"Bonds, D. E. et al. Risk of fracture in women with type 2 diabetes: The women\u2019s health initiative observational study. J. Clin. Endocrinol. Metab. 91, 3404\u20133410. https:\/\/doi.org\/10.1210\/jc.2006-0614 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"15104_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/aje\/kwm106","volume":"166","author":"M Janghorbani","year":"2007","unstructured":"Janghorbani, M., Van Dam, R. M., Willett, W. C. & Hu, F. B. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am. J. Epidemiol. 166, 495\u2013505. https:\/\/doi.org\/10.1093\/aje\/kwm106 (2007).","journal-title":"Am. J. Epidemiol."},{"key":"15104_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00198-006-0253-4","volume":"18","author":"P Vestergaard","year":"2007","unstructured":"Vestergaard, P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes\u2013a meta-analysis. Osteoporos. Int. 18, 427\u2013444. https:\/\/doi.org\/10.1007\/s00198-006-0253-4 (2007).","journal-title":"Osteoporos. Int."},{"key":"15104_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00223-007-9003-7","volume":"80","author":"M Yamamoto","year":"2007","unstructured":"Yamamoto, M., Yamaguchi, T., Yamauchi, M., Kaji, H. & Sugimoto, T. Bone mineral density is not sensitive enough to assess the risk of vertebral fractures in type 2 diabetic women. Calcif Tissue Int. 80, 353\u2013358. https:\/\/doi.org\/10.1007\/s00223-007-9003-7 (2007).","journal-title":"Calcif Tissue Int."},{"key":"15104_CR9","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1359\/jbmr.080323","volume":"23","author":"LJ Melton","year":"2008","unstructured":"Melton, L. J., Leibson, C. L., Achenbach, S. J., Therneau, T. M., Khosla, S. & rd,, & Fracture risk in type 2 diabetes: Update of a population-based study. J. Bone Min. Res. 23, 1334\u20131342. https:\/\/doi.org\/10.1359\/jbmr.080323 (2008).","journal-title":"J. Bone Min. Res."},{"key":"15104_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10654-012-9674-x","volume":"27","author":"L Ma","year":"2012","unstructured":"Ma, L. et al. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur. J. Epidemiol. 27, 319\u2013332. https:\/\/doi.org\/10.1007\/s10654-012-9674-x (2012).","journal-title":"Eur. J. Epidemiol."},{"key":"15104_CR11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/jbmr.556","volume":"27","author":"LM Giangregorio","year":"2012","unstructured":"Giangregorio, L. M. et al. FRAX underestimates fracture risk in patients with diabetes. J. Bone Min. Res. 27, 301\u2013308. https:\/\/doi.org\/10.1002\/jbmr.556 (2012).","journal-title":"J. Bone Min. Res."},{"key":"15104_CR12","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1002\/jbmr.3538","volume":"33","author":"WD Leslie","year":"2018","unstructured":"Leslie, W. D. et al. Comparison of methods for improving fracture risk assessment in diabetes: The manitoba BMD registry. J. Bone Min. Res. 33, 1923\u20131930. https:\/\/doi.org\/10.1002\/jbmr.3538 (2018).","journal-title":"J. Bone Min. Res."},{"key":"15104_CR13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1136\/postgradmedj-2018-136002","volume":"95","author":"YS Wang","year":"2019","unstructured":"Wang, Y. S. et al. Increased serum\/plasma fibroblast growth factor 21 in type 2 diabetes mellitus: A systematic review and meta-analysis. Postgrad. Med. J. 95, 134\u2013139. https:\/\/doi.org\/10.1136\/postgradmedj-2018-136002 (2019).","journal-title":"Postgrad. Med. J."},{"key":"15104_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/ijo.2014.76","volume":"39","author":"JM Gallego-Escuredo","year":"2015","unstructured":"Gallego-Escuredo, J. M. et al. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients. Int. J. Obes. (Lond). 39, 121\u2013129. https:\/\/doi.org\/10.1038\/ijo.2014.76 (2015).","journal-title":"Int. J. Obes. (Lond)"},{"key":"15104_CR15","doi-asserted-by":"publisher","first-page":"e000776","DOI":"10.1136\/bmjdrc-2019-000776","volume":"7","author":"ES Hong","year":"2019","unstructured":"Hong, E. S. et al. Plasma fibroblast growth factor 21 levels increase with ectopic fat accumulation and its receptor levels are decreased in the visceral fat of patients with type 2 diabetes. BMJ Open. Diabetes Res. Care. 7, e000776. https:\/\/doi.org\/10.1136\/bmjdrc-2019-000776 (2019).","journal-title":"BMJ Open. Diabetes Res. Care"},{"key":"15104_CR16","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1210\/clinem\/dgac729","volume":"108","author":"A Post","year":"2023","unstructured":"Post, A. et al. Circulating FGF21 concentration, fasting plasma glucose, and the risk of type 2 diabetes: results from the PREVEND study. J. Clin. Endocrinol. Metab. 108, 1387\u20131393. https:\/\/doi.org\/10.1210\/clinem\/dgac729 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"15104_CR17","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1210\/jc.2014-3465","volume":"100","author":"CH Lee","year":"2015","unstructured":"Lee, C. H. et al. Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria. J. Clin. Endocrinol. Metab. 100, 1368\u20131375. https:\/\/doi.org\/10.1210\/jc.2014-3465 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"15104_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jdiacomp.2016.11.012","volume":"31","author":"L Xu","year":"2017","unstructured":"Xu, L. et al. Associations between FGF21, osteonectin and bone turnover markers in type 2 diabetic patients with albuminuria. J. Diabetes Complications  31, 583\u2013588. https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.11.012 (2017).","journal-title":"J. Diabetes Complications"},{"key":"15104_CR19","doi-asserted-by":"publisher","unstructured":"Lee, C. H. et al. Role of Circulating fibroblast growth factor 21 measurement in primary prevention of coronary heart disease among Chinese patients with type 2 diabetes mellitus. J. Am. Heart Assoc. 6 https:\/\/doi.org\/10.1161\/jaha.116.005344 (2017).","DOI":"10.1161\/jaha.116.005344"},{"key":"15104_CR20","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s12902-023-01523-y","volume":"23","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. Increased circulating FGF21 level predicts the burden of metabolic demands and risk of vascular diseases in adults with type 2 diabetes. BMC Endocr. Disord.  23, 272. https:\/\/doi.org\/10.1186\/s12902-023-01523-y (2023).","journal-title":"BMC Endocr. Disord."},{"key":"15104_CR21","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s00125-014-3458-7","volume":"58","author":"KL Ong","year":"2015","unstructured":"Ong, K. L. et al. The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the fenofibrate intervention and event lowering in diabetes study. Diabetologia 58, 464\u2013473. https:\/\/doi.org\/10.1007\/s00125-014-3458-7 (2015).","journal-title":"Diabetologia"},{"key":"15104_CR22","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/s41366-018-0080-7","volume":"42","author":"B Andersen","year":"2018","unstructured":"Andersen, B. et al. FGF21 decreases body weight without reducing food intake or bone mineral density in high-fat fed obese rhesus macaque monkeys. Int. J. Obes. (Lond) . 42, 1151\u20131160. https:\/\/doi.org\/10.1038\/s41366-018-0080-7 (2018).","journal-title":"Int. J. Obes. (Lond)"},{"key":"15104_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","volume":"23","author":"S Talukdar","year":"2016","unstructured":"Talukdar, S. et al. A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell. Metab. 23, 427\u2013440. https:\/\/doi.org\/10.1016\/j.cmet.2016.02.001 (2016).","journal-title":"Cell. Metab."},{"key":"15104_CR24","doi-asserted-by":"publisher","first-page":"625287","DOI":"10.3389\/fphys.2021.625287","volume":"12","author":"H Sun","year":"2021","unstructured":"Sun, H., Sherrier, M. & Li, H. Skeletal muscle and bone - emerging targets of fibroblast growth factor-21. Front. Physiol. 12, 625287. https:\/\/doi.org\/10.3389\/fphys.2021.625287 (2021).","journal-title":"Front. Physiol."},{"key":"15104_CR25","doi-asserted-by":"publisher","first-page":"100548","DOI":"10.1016\/j.bj.2022.07.002","volume":"46","author":"Y Tang","year":"2023","unstructured":"Tang, Y. & Zhang, M. Fibroblast growth factor 21 and bone homeostasis. Biomed. J. 46, 100548. https:\/\/doi.org\/10.1016\/j.bj.2022.07.002 (2023).","journal-title":"Biomed. J."},{"key":"15104_CR26","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2337\/dc18-1486","volume":"42","author":"WA Davis","year":"2019","unstructured":"Davis, W. A., Hamilton, E. J., Bruce, D. G. & Davis, T. M. E. Development and validation of a simple hip fracture risk prediction tool for type 2 diabetes: The fremantle diabetes study phase I. Diabetes Care  42, 102\u2013109. https:\/\/doi.org\/10.2337\/dc18-1486 (2019).","journal-title":"Diabetes Care"},{"key":"15104_CR27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.bone.2019.02.003","volume":"122","author":"I Kanazawa","year":"2019","unstructured":"Kanazawa, I. et al. A scoring assessment tool for the risk of vertebral fractures in patients with type 2 diabetes mellitus. Bone 122, 38\u201344. https:\/\/doi.org\/10.1016\/j.bone.2019.02.003 (2019).","journal-title":"Bone"},{"key":"15104_CR28","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1007\/s00198-022-06425-8","volume":"33","author":"XK Kong","year":"2022","unstructured":"Kong, X. K. et al. Major osteoporosis fracture prediction in type 2 diabetes: A derivation and comparison study. Osteoporos. Int. 33, 1957\u20131967. https:\/\/doi.org\/10.1007\/s00198-022-06425-8 (2022).","journal-title":"Osteoporos. Int."},{"key":"15104_CR29","doi-asserted-by":"publisher","first-page":"e0203533","DOI":"10.1371\/journal.pone.0203533","volume":"13","author":"D Mart\u00ednez-Laguna","year":"2018","unstructured":"Mart\u00ednez-Laguna, D. et al. Fracture risk in type 2 diabetic patients: A clinical prediction tool based on a large population-based cohort. PLoS One 13, e0203533. https:\/\/doi.org\/10.1371\/journal.pone.0203533 (2018).","journal-title":"PLoS One"},{"key":"15104_CR30","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2147\/tcrm.S131945","volume":"13","author":"A Moayeri","year":"2017","unstructured":"Moayeri, A. et al. Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: A systematic review and meta-analysis. Ther. Clin. Risk Manag.  13, 455\u2013468. https:\/\/doi.org\/10.2147\/tcrm.S131945 (2017).","journal-title":"Ther. Clin. Risk Manag"},{"key":"15104_CR31","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s00198-021-05934-2","volume":"32","author":"K Hidayat","year":"2021","unstructured":"Hidayat, K., Fang, Q. L., Shi, B. M. & Qin, L. Q. Influence of glycemic control and hypoglycemia on the risk of fracture in patients with diabetes mellitus: A systematic review and meta-analysis of observational studies. Osteoporos. Int. 32, 1693\u20131704. https:\/\/doi.org\/10.1007\/s00198-021-05934-2 (2021).","journal-title":"Osteoporos. Int."},{"key":"15104_CR32","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2337\/dc12-1168","volume":"36","author":"AL Schneider","year":"2013","unstructured":"Schneider, A. L. et al. Diabetes and risk of fracture-related hospitalization: the atherosclerosis risk in communities study. Diabetes Care 36, 1153\u20131158. https:\/\/doi.org\/10.2337\/dc12-1168 (2013).","journal-title":"Diabetes Care"},{"key":"15104_CR33","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1111\/obr.12885","volume":"20","author":"K Hidayat","year":"2019","unstructured":"Hidayat, K., Du, X., Wu, M. J. & Shi, B. M. The use of metformin, insulin, sulphonylureas, and Thiazolidinediones and the risk of fracture: Systematic review and meta-analysis of observational studies. Obes. Rev. 20, 1494\u20131503. https:\/\/doi.org\/10.1111\/obr.12885 (2019).","journal-title":"Obes. Rev."},{"key":"15104_CR34","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.18632\/aging.204643","volume":"15","author":"CL Yen","year":"2023","unstructured":"Yen, C. L. et al. Pioglitazone reduces cardiovascular events and dementia but increases bone fracture in elderly patients with type 2 diabetes mellitus: A national cohort study. Aging (Albany NY). 15, 2721\u20132733. https:\/\/doi.org\/10.18632\/aging.204643 (2023).","journal-title":"Aging (Albany NY)"},{"key":"15104_CR35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.bone.2014.08.010","volume":"68","author":"ZN Zhu","year":"2014","unstructured":"Zhu, Z. N., Jiang, Y. F. & Ding, T. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone 68, 115\u2013123. https:\/\/doi.org\/10.1016\/j.bone.2014.08.010 (2014).","journal-title":"Bone"},{"key":"15104_CR36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00198-020-05681-w","volume":"32","author":"BAM Larsson","year":"2021","unstructured":"Larsson, B. A. M. et al. The timed up and go test predicts fracture risk in older women independently of clinical risk factors and bone mineral density. Osteoporos. Int. 32, 75\u201384. https:\/\/doi.org\/10.1007\/s00198-020-05681-w (2021).","journal-title":"Osteoporos. Int."},{"key":"15104_CR37","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1001\/archinternmed.2011.434","volume":"171","author":"K Zhu","year":"2011","unstructured":"Zhu, K., Devine, A., Lewis, J. R., Dhaliwal, S. S. & Prince, R. L. Timed up and go\u2019 test and bone mineral density measurement for fracture prediction. Arch. Intern. Med. 171, 1655\u20131661. https:\/\/doi.org\/10.1001\/archinternmed.2011.434 (2011).","journal-title":"Arch. Intern. Med."},{"key":"15104_CR38","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.bone.2019.07.018","volume":"127","author":"SM Jeong","year":"2019","unstructured":"Jeong, S. M. et al. Timed up-and-go test is a useful predictor of fracture incidence. Bone 127, 474\u2013481. https:\/\/doi.org\/10.1016\/j.bone.2019.07.018 (2019).","journal-title":"Bone"},{"key":"15104_CR39","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1007\/s40520-019-01417-x","volume":"32","author":"J Bai","year":"2020","unstructured":"Bai, J., Gao, Q., Wang, C. & Dai, J. Diabetes mellitus and risk of low-energy fracture: A meta-analysis. Aging Clin. Exp. Res. 32, 2173\u20132186. https:\/\/doi.org\/10.1007\/s40520-019-01417-x (2020).","journal-title":"Aging Clin. Exp. Res."},{"key":"15104_CR40","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1007\/s00198-017-4183-0","volume":"28","author":"P Jia","year":"2017","unstructured":"Jia, P. et al. Risk of low-energy fracture in type 2 diabetes patients: A meta-analysis of observational studies. Osteoporos. Int. 28, 3113\u20133121. https:\/\/doi.org\/10.1007\/s00198-017-4183-0 (2017).","journal-title":"Osteoporos. Int."},{"key":"15104_CR41","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1007\/s00198-021-06032-z","volume":"32","author":"J Ha","year":"2021","unstructured":"Ha, J. et al. Comparison of fracture risk between type 1 and type 2 diabetes: A comprehensive real-world data. Osteoporos. Int. 32, 2543\u20132553. https:\/\/doi.org\/10.1007\/s00198-021-06032-z (2021).","journal-title":"Osteoporos. Int."},{"key":"15104_CR42","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/jbmr.1729","volume":"28","author":"M Premaor","year":"2013","unstructured":"Premaor, M. et al. Predictive value of FRAX for fracture in obese older women. J. Bone Min. Res. 28, 188\u2013195. https:\/\/doi.org\/10.1002\/jbmr.1729 (2013).","journal-title":"J. Bone Min. Res."},{"key":"15104_CR43","first-page":"7","volume":"51","author":"ME Leite Duarte","year":"1996","unstructured":"Leite Duarte, M. E. & da Silva, R. D. Histomorphometric analysis of the bone tissue in patients with non-insulin-dependent diabetes (DMNID). Rev. Hosp. Clin. Fac. Med. Sao Paulo. 51, 7\u201311 (1996).","journal-title":"Rev. Hosp. Clin. Fac. Med. Sao Paulo"},{"key":"15104_CR44","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/jbmr.2936","volume":"32","author":"X Li","year":"2017","unstructured":"Li, X. et al. FGF21 is not a major mediator for bone homeostasis or metabolic actions of PPAR\u03b1 and PPAR\u03b3 agonists. J. Bone Min. Res. 32, 834\u2013845. https:\/\/doi.org\/10.1002\/jbmr.2936 (2017).","journal-title":"J. Bone Min. Res."},{"key":"15104_CR45","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s00774-016-0745-z","volume":"35","author":"N Charoenphandhu","year":"2017","unstructured":"Charoenphandhu, N. et al. Fibroblast growth factor-21 restores insulin sensitivity but induces aberrant bone microstructure in obese insulin-resistant rats. J. Bone Miner. Metab. 35, 142\u2013149. https:\/\/doi.org\/10.1007\/s00774-016-0745-z (2017).","journal-title":"J. Bone Miner. Metab."},{"key":"15104_CR46","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1210\/er.2017-00016","volume":"38","author":"H Staiger","year":"2017","unstructured":"Staiger, H., Keuper, M., Berti, L., Hrabe de Angelis, M. & H\u00e4ring, H. U. Fibroblast growth factor 21-metabolic role in mice and men. Endocr. Rev. 38, 468\u2013488. https:\/\/doi.org\/10.1210\/er.2017-00016 (2017).","journal-title":"Endocr. Rev."},{"key":"15104_CR47","doi-asserted-by":"publisher","first-page":"967375","DOI":"10.3389\/fmed.2022.967375","volume":"9","author":"K Falamarzi","year":"2022","unstructured":"Falamarzi, K. et al. The role of FGF21 and its analogs on liver associated diseases. Front. Med. (Lausanne) 9, 967375. https:\/\/doi.org\/10.3389\/fmed.2022.967375 (2022).","journal-title":"Front. Med. (Lausanne)"},{"key":"15104_CR48","doi-asserted-by":"publisher","first-page":"36","DOI":"10.5114\/aoms\/98948","volume":"18","author":"I Cantero","year":"2022","unstructured":"Cantero, I. et al. Fibroblast growth factor 21 levels and liver inflammatory biomarkers in obese subjects after weight loss. Arch. Med. Sci. 18, 36\u201344. https:\/\/doi.org\/10.5114\/aoms\/98948 (2022).","journal-title":"Arch. Med. Sci."},{"key":"15104_CR49","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3389\/fendo.2018.00800","volume":"9","author":"F Xiao","year":"2018","unstructured":"Xiao, F. et al. Independent association of serum fibroblast growth factor 21 levels with impaired liver enzymes in hyperthyroid patients. Front. Endocrinol. (Lausanne)    9, 800. https:\/\/doi.org\/10.3389\/fendo.2018.00800 (2018).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"15104_CR50","doi-asserted-by":"publisher","first-page":"535","DOI":"10.11622\/smedj.2017044","volume":"58","author":"A Phrommintikul","year":"2017","unstructured":"Phrommintikul, A. et al. Management of atherosclerosis risk factors for patients at high cardiovascular risk in real-world practice: A multicentre study. Singap. Med. J. 58, 535\u2013542. https:\/\/doi.org\/10.11622\/smedj.2017044 (2017).","journal-title":"Singap. Med. J."},{"key":"15104_CR51","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm, E. et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J. Clin. Epidemiol. 61, 344\u2013349. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008 (2008).","journal-title":"J. Clin. Epidemiol."},{"key":"15104_CR52","unstructured":"Centre for Metabolic Bone Diseases, University of Sheffield, UK[Internet]: The Fracture Risk Assessment Tool (FRAX\u00ae). May 1, 2013. Accessed June 2023. https:\/\/www.sheffield.ac.uk\/FRAX\/tool.aspx?country=57"},{"key":"15104_CR53","unstructured":"World Health Organization. Regional Office for the Western Pacific. The Asia-Pacific perspective: redefining obesity and its treatment. Coordinated by the International Diabetes Institute; co-sponsored jointly by the Regional Office for the Western Pacific (WPRO), World Health Organization, the International Association for the Study of Obesity and the International Obesity Task Force (Health Communications Australia, Sydney, 2000)."},{"key":"15104_CR54","unstructured":"World Health Organization. Waist circumference and waist-hip ratio: report of a WHO expert consulation, Geneva, 8\u201311 December 2008. (2011)."},{"key":"15104_CR55","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","volume":"23","author":"KG Alberti","year":"2006","unstructured":"Alberti, K. G., Zimmet, P. & Shaw, J. Metabolic syndrome\u2013a new world-wide definition. A consensus statement from the international diabetes federation. Diabet. Med. 23, 469\u2013480. https:\/\/doi.org\/10.1111\/j.1464-5491.2006.01858.x (2006).","journal-title":"Diabet. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15104-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15104-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15104-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T03:47:22Z","timestamp":1755575242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15104-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15104"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-15104-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"14 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29848"}}